The rationale of dose–response curves in selecting cancer drug dosing

Jennifer H. Martin, Simon Dimmitt

Research output: Contribution to journalReview articlepeer-review

8 Citations (Scopus)


Drug development for cancer chemotherapy has an interesting history. A mix of serendipity, animal, cell line, and standard pharmacological principles of dose, dose-response, dose-concentration, dose intensity and combination therapies have been used to develop optimal dosing schedules. However in practice, significant gaps in the translation of preclinical to clinical dosing schedules persist, and clinical development has instead moved to new drug development. A older chemotherapies are still the backbone of most solid tumour schedules, therapeutic drug monitoring has emerged as a method for optimising the dose for individual patients.

Original languageEnglish
Pages (from-to)2198-2204
Number of pages7
JournalBritish Journal of Clinical Pharmacology
Issue number10
Publication statusPublished - 1 Oct 2019


Dive into the research topics of 'The rationale of dose–response curves in selecting cancer drug dosing'. Together they form a unique fingerprint.

Cite this